As part of post-approval regulatory commitments for pazopanib, a post-marketing safety study was conducted in three electronic medical record (EMR) databases to examine the incidence of hepatotoxicity in RCC patients treated with pazopanib or comparator anti-VEGF drugs. This evidence concerns the gene VEGFA and renal cell carcinoma.